the role of mast cell-derived lipid mediators in anaphylaxis.

[THE ROLE OF MAST CELL-DERIVED LIPID MEDIATORS IN ANAPHYLAXIS]. Arerugi. 2018;67(1):31-36 Authors: Nakamura T PMID: 29459523 [PubMed - in process]
Source: Allergology International - Category: Allergy & Immunology Tags: Arerugi Source Type: research

Related Links:

Publication date: Available online 15 February 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Samantha Platt, Scott H. Sicherer
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
We report a case of an 8-year-old boy who developed a cochineal allergy.Current disease history: He has been suffering from atopic dermatitis, bronchial asthma, and food allergies since childhood. At the age of seven, he experienced an unknown anaphylaxis reaction twice. When he was 8 years old, he ate a frankfurter containing hypoallergenic cochineal for the first time; cold sweat, intraoral discomfort, respiratory distress, and urticaria appeared throughout the body. His skin prick tests were positive, with a result of 2+to frankfurter and cochineal dyes (color value 0.1 and 0.01). In the immunoblot assay, binding of IgE...
Source: Arerugi - Category: Allergy & Immunology Authors: Tags: Arerugi Source Type: research
CONCLUSION: These data suggest that FDEIA and post-OIT-FDEIA patients can exhibit similar clinical symptoms, and all symptoms occurred in 60 minutes after exercise. PMID: 32051367 [PubMed - in process]
Source: Arerugi - Category: Allergy & Immunology Authors: Tags: Arerugi Source Type: research
ConclusionNo patient experienced adverse events directly related to gadoterate meglumine. Only two adverse events were reported to have occurred in the initial 2  h after the exam, while the rest were reported on the 24-h follow-up call. The higher reported rate of adverse events in this study may be related to concomitant sedation/anesthesia as well as to overreporting from parents on the 24-h follow-up questionnaire. The study confirms a good safety profi le for gadoterate meglumine in this very sensitive population.
Source: Pediatric Radiology - Category: Radiology Source Type: research
PMID: 32053569 [PubMed - as supplied by publisher]
Source: Chinese Medical Journal - Category: General Medicine Authors: Tags: Chin Med J (Engl) Source Type: research
Hi team, I have a patient who has anaphylactic reaction to an IM steroid 10 years ago- details unknown but good history including ICU stay for 3 days. Do you guys have allergist that test for Depomedrol/ decadron/ Kenalog? What other options for epidural Thanks
Source: Student Doctor Network - Category: Universities & Medical Training Authors: Tags: Pain Medicine Source Type: forums
Deaths due to food allergy are incredibly rare (1), but it is now understood that food is the most commonly identified trigger of anaphylaxis (2). In the United States, deaths from food anaphylaxis are broadly estimated to occur at a rate of 5-200 cases per year (3).
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Perspective Source Type: research
PMID: 32057931 [PubMed - as supplied by publisher]
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Ann Allergy Asthma Immunol Source Type: research
CONCLUSIONS: VVN has become the commonest cause of Hymenoptera anaphylaxis in our area. Most cases report no previous VVN stings. Their sensitization pattern is similar to that of patients with anaphylaxis to other Vespidae. Specific IgE to antigen-5 from VVN, Vespula spp., and Polistes dominula are strongly correlated in patients with VVN anaphylaxis. PMID: 32043465 [PubMed - as supplied by publisher]
Source: Journal of Investigational Allergology and Clinical Immunology - Category: Allergy & Immunology Authors: Tags: J Investig Allergol Clin Immunol Source Type: research
RARITAN, NJ, February 10, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of DARZALEX® (daratumumab) in combination with Kyprolis® (carfilzomib) and dexamethasone (DKd) for relapsed/refractory multiple myeloma. The sBLA is supported by results from the Phase 3 CANDOR study, which compared treatment with DKd to carfilzomib and dexamethasone (Kd) in patients with multiple myeloma who relapsed after one to three prior lines of therapy. “Wh...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
More News: Anaphylactic Shock